A new trading day began on Tuesday, with Neogenomics Inc (NASDAQ: NEO) stock price up 4.32% from the previous day of trading, before settling in for the closing price of $7.17. NEO’s price has ranged from $6.08 to $19.11 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 10.07% over the past five years. Meanwhile, its annual earnings per share averaged 38.64%. With a float of $127.02 million, this company’s outstanding shares have now reached $128.36 million.
Let’s look at the performance matrix of the company that is accounted for 2200 employees. In terms of profitability, gross margin is 43.79%, operating margin of -13.06%, and the pretax margin is -11.58%.
Neogenomics Inc (NEO) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Diagnostics & Research Industry. The insider ownership of Neogenomics Inc is 1.30%, while institutional ownership is 99.73%. The most recent insider transaction that took place on May 27 ’25, was worth 38,000. In this transaction Director of this company bought 5,000 shares at a rate of $7.60, taking the stock ownership to the 5,000 shares. Before that another transaction happened on May 12 ’25, when Company’s Pres & Chief Operating Officer bought 5,700 for $8.58, making the entire transaction worth $48,895. This insider now owns 108,280 shares in total.
Neogenomics Inc (NEO) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 38.64% per share during the next fiscal year.
Neogenomics Inc (NASDAQ: NEO) Trading Performance Indicators
Here are Neogenomics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.94. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.61, a number that is poised to hit 0.03 in the next quarter and is forecasted to reach 0.30 in one year’s time.
Technical Analysis of Neogenomics Inc (NEO)
Neogenomics Inc (NASDAQ: NEO) saw its 5-day average volume 1.57 million, a negative change from its year-to-date volume of 1.76 million. As of the previous 9 days, the stock’s Stochastic %D was 27.90%. Additionally, its Average True Range was 0.49.
During the past 100 days, Neogenomics Inc’s (NEO) raw stochastic average was set at 10.74%, which indicates a significant decrease from 31.40% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 46.12% in the past 14 days, which was lower than the 106.21% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.55, while its 200-day Moving Average is $13.12. Nevertheless, the first resistance level for the watch stands at $7.68 in the near term. At $7.88, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.18. If the price goes on to break the first support level at $7.18, it is likely to go to the next support level at $6.88. Assuming the price breaks the second support level, the third support level stands at $6.68.
Neogenomics Inc (NASDAQ: NEO) Key Stats
With a market capitalization of 962.64 million, the company has a total of 128,695K Shares Outstanding. Currently, annual sales are 660,570 K while annual income is -78,730 K. The company’s previous quarter sales were 168,040 K while its latest quarter income was -25,920 K.
